Phase II trial of titanocene dichloride in advanced renal-cell carcinoma.
Titanocene dichloride was capable of inhibiting the growth of different types of human tumors in vitro. A total of 14 patients with metastatic renal-cell carcinoma (RCC) received 270 mg/m2 titanocene dichloride every 3 weeks for 6 weeks. Although the toxicities and side effects encountered were mild to moderate, no partial or complete response was detectable. In conclusion, titanocene dichloride has no advantage in the therapy of RCC.
Lümmen
G
G
Department of Urology, University of Essen, Medical School, Germany.
Sperling
H
H
Luboldt
H
H
Otto
T
T
Rübben
H
H
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D010865:Pilot Projects; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D009942:Organometallic Compounds; C020528:titanocene dichloride